doi: 10.1161/hc5001.102111
(Circulation. 2001;104:3030.)
© 2001 American Heart Association, Inc.
Brief Rapid Communications |
Novel PRKAG2 Mutation Responsible for the Genetic Syndrome of Ventricular Preexcitation and Conduction System Disease With Childhood Onset and Absence of Cardiac Hypertrophy
From the Section of Cardiology, Baylor College of Medicine, Houston, Tex.
Correspondence to Robert Roberts, MD, Don W. Chapman Professor of Medicine, Professor of Medicine and Cell Biology, Department of Medicine, Section of Cardiology, 6550 Fannin, MS SM677, Baylor College of Medicine, Houston, TX 77030. E-mail rroberts{at}bcm.tmc.edu
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background— We recently reported a mutation in the PRKAG2 gene to be responsible for a familial syndrome of ventricular preexcitation, atrial fibrillation, conduction defects, and cardiac hypertrophy. We now report a novel mutation in PRKAG2 causing Wolff-Parkinson-White syndrome and conduction system disease with onset in childhood and the absence of cardiac hypertrophy.
Methods and Results— DNA was extracted from white blood cells obtained from family members. PRKAG2 exons were amplified by polymerase chain reaction and were screened for mutations by direct sequencing. The genomic organization of the PRKAG2 gene was determined using inter-exon long-range polymerase chain reaction for cDNA sequence not available in the genome database. A missense mutation, Arg531Gly, was identified in all affected individuals but was absent in 150 unrelated individuals. The PRKAG2 gene was determined to consist of 16 exons and is at least 280 kb in size.
Conclusions— We identified a novel mutation (Arg531Gly) in the 
-2 regulatory subunit (PRKAG2) of AMP-activated protein kinase (AMPK) to be responsible for a syndrome associated with ventricular preexcitation and early onset of atrial fibrillation and conduction disease. These observations confirm an important functional role of AMPK in the regulation of ion channels specific to cardiac tissue. The identification of the cardiac ion channel(s) serving as substrate for AMPK not only would provide insight into the molecular basis of atrial fibrillation and heart block but also may suggest targets for the development of more specific therapy for these common rhythm disturbances.
Key Words: Wolff-Parkinson-White syndrome • genetics • hypertrophy • arrhythmia
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The Wolff-Parkinson-White (WPW) syndrome is characterized by electrocardiographic evidence of ventricular preexcitation, which predisposes to supraventricular arrhythmias.1 Tachycardias mediated by accessory atrioventricular connections, the anatomic substrate for WPW, are the most common tachycardias in children <12 years of age.2 WPW as a cause of sudden cardiac death (SCD), presumably as a result of rapidly conducting atrial fibrillation, is well recognized.3 The prevalence of WPW as a cause of SCD remains unknown because histological evidence is seldom sought at autopsy. However, a recent study of SCD victims <35 years of age for whom ECGs were available identified WPW in 10.5% of cases.4 Atrioventricular connections were confirmed by histological examination.4 We recently identified5 2 families with familial ventricular preexcitation associated with a high incidence of atrial fibrillation, conduction defects, and cardiac hypertrophy, and we established the responsible genetic defect to be a mutation in the gene that encodes the
-2 regulatory subunit (PRKAG2) of AMP-activated protein kinase (AMPK). Paroxysmal atrial fibrillation was particularly frequent, and chronic atrial fibrillation was present in 80% of patients >50 years of age.
See p 3014
We now report a third, unrelated family, which also has ventricular preexcitation, atrial fibrillation, and conduction defects. The third family has more severe disease, with onset in childhood instead of adolescence. No cardiac hypertrophy is present. DNA analysis of the third family shows the defect to be a novel mutation in PRKAG2. These results also emphasize that AMPK plays a significant role in cardiac development and ion channel regulation.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Study Cohort
Informed, written consent was obtained from study participants. Subjects were evaluated by a detailed history, physical examination, 12-lead electrocardiography, and 2D echocardiography. Study participants consisted of a proband with 8 family members. Ventricular preexcitation was diagnosed on the basis of a short PR interval (<120 ms) with widened QRS interval (>110 ms) and abnormal initial QRS vector (
wave). Conduction system disease was diagnosed if evidence of sinus node dysfunction or atrioventricular block was demonstrated on ECG. Twelve-lead ECGs were retrieved from archived medical records when possible.
Mutation Detection and Analysis
Exon-intron boundaries of the protein-encoding sequences of PRKAG2 were identified in the GenBank database, as previously described.5 For protein-encoding sequences (base pairs 205 to 556) not available by the sequence sampling approach, primers were designed from cDNA sequences and inter-exon long-range polymerase chain reaction (PCR) (Elongase, GIBCO) was used to determine exon-intron boundaries. Intronic primers were designed on the basis of exon-intron boundaries. Genomic DNA fragments were amplified by PCR, and the products were purified using the QIAquick PCR purification kit (QIAGEN). Direct sequencing reactions were performed in both the sense and antisense directions on an ABI PRISM 377 (Perkin-Elmer Applied Biosystems) using big dye chemistry.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Clinical Findings
A 3-generation family with 4 affected individuals diagnosed as having Wolff-Parkinson-White syndrome was studied. The proband (II-1 in Figure 1A), a 43-year-old white male, experienced recurrent syncopal events beginning at age 2 and extending through adolescence that were associated with atrial fibrillation and heart rates approaching 230 bpm (Figure 2A and 2B). Ventricular preexcitation on resting ECG was noted at age 2. By age 10, he had undergone 6 electrical cardioversions and continued to have paroxysms of rapid atrial fibrillation and 1:1 atrial flutter. At age 13, paroxysms of atrial fibrillation were followed by ventricular escape rhythms of right bundle branch morphology at rates of 20 to 30 bpm with resultant syncope. A permanent pacemaker was implanted. He has been in chronic atrial fibrillation since age 15 and is currently dependent on ventricular pacing. Since age 33, the patient has required antihypertensive therapy for persistent hypertension. Recent 2D echocardiography showed normal left ventricular (LV) function, interventricular septal thickness of 9 mm, and maximal LV free wall thickness of 11 mm (Figure 2C). LV mass is normal when corrected for body surface area. The proband’s father (I-1), diagnosed with Wolff-Parkinson-White syndrome, died suddenly at age 31. The proband’s younger brother (II-3), now 41 years of age, presented with a "seizure" at age 6, which was attributed to a tachycardia associated with Wolff-Parkinson-White syndrome. This patient experienced a clinical course similar to the proband, requiring permanent pacemaker implantation at age 22 because of recurrent syncope in the setting of severe sinus bradycardia and chronotropic incompetence. Two-dimensional echo at age 41 is normal. Interestingly, he has required antihypertensive therapy since age 23. An 8-year-old daughter (III-3) of the proband shows evidence of ventricular preexcitation on ECG but remains asymptomatic.
|
|
Genomic Structure of the PRKAG2 Gene
We determined that the PRKAG2 cDNA sequence extending from base pairs 205 to 556 encode 2 exons, exon 2 (base pairs 205 to 276) and exon 3 (base pairs 277 to 556), respectively. The splice junctions comply with the ag-gt rule and are as follows: exon 2, 5'-tc ca cc ct agAC CTGAGCTCC...CCTCT CG AAAGgtaagacctc-3' and exon 3, 5'-ttttctgcag GTGGACAGCC-C... CTC CA GA AA AAgtaagacctt-3'. The genomic position of exons 1 and 4 to 16 were determined from P1-derived artificial chromosome clones RP11-796I2 (AC074257), RP5-1127D14 (AC006358), RP4-563H24 (AC006966). Analysis of genomic sequence data indicates the PRKAG2 gene is 
280 kb in size located at 7q36 of chromosome 7.
Missense Mutation in the PRKAG2 Gene
A missense mutation, Arg531Gly, in exon 15 of PRKAG2 was identified and shown to be present in all living affected family members. The mutation results from guanine (G) substituted for cytosine (C) at nucleotide 1681 (GenBank accession number AJ249976). This base pair substitution creates a restriction enzyme recognition site for NIaIII. Restriction enzyme digestion with NIaIII of DNA from family members provided confirmation of the mutation, showing the expected novel digestion pattern only in the affected members. Direct DNA sequencing of 150 unrelated healthy white individuals did not show this mutation.
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
We identified a kindred with ventricular preexcitation, rapidly conducting paroxysms of atrial fibrillation and flutter, with progression to high-grade conduction disease. Clinical presentation of symptomatic arrhythmias occurred in early childhood, compared with a clinical presentation in adulthood in the 2 families we have reported previously.5 Despite the early onset of clinical disease, left ventricular hypertrophy was not detected even though affected individuals were in their fifth decade. The absence or variable expression of cardiac hypertrophy in this syndrome may reflect the influence of genetic background. In previous families, we recently demonstrated a mutation in PRKAG2 to be responsible for this clinical syndrome.5 The disease in the present family is caused by a novel mutation (Arg531Gly) in the same gene. The causality of the mutation for the phenotype in this family is confirmed by the following: (1) The mutation was present in all affected family members; (2) the mutation replaces a highly conserved, positively charged arginine residue with a neutrally charged glycine; and (3) the mutation was not present in 150 unrelated normal subjects.
Determination of the intron-exon structure of the PRKAG2 gene showed that it consists of 16 exons and is 280 kb in size. Recently, it was determined that a smaller transcription product of PRKAG2 exists as a result of an alternative transcription initiation site in intron 4.6 Thus, this smaller transcript corresponds to exons 5 to 12 of the full-length transcription product. The full-length and truncated transcripts, denoted PRKAG2a and PRKAG2b, respectively, are highly expressed in cardiac tissue.6,7 The previously and currently described mutations are present in exons 7 and 15, and are therefore common to both PRKAG2 transcription products.
AMPK, a serine/threonine kinase, is known to have multiple cellular functions, which may account for the diverse phenotype of ventricular preexcitation, conduction system disease, and cardiac hypertrophy, as has been emphasized in recent studies.5,8 Evidence suggests that AMPK regulates gene transcription,9 and mutations in transcription factors are known to induce congenital heart malformations.10 The mutant AMPK presumably alters atrioventricular septation during cardiogenesis, leading to the presence of accessory atrioventricular fibers responsible for ventricular preexcitation. Atrial fibrillation may occur in 
15% of sporadic WPW cases.11 The much higher incidence of atrial fibrillation and conduction defects observed in this syndrome suggests that AMPK, through phosphorylation, regulates cardiac ion channels.12 The identification of the cardiac ion channel(s) serving as substrate for AMPK not only would provide insight into the molecular basis of these common rhythm disturbances but also would suggest targets for the development of more specific therapy. This is particularly significant in consideration of the fact that the molecular mechanism for atrial fibrillation from any cause remains elusive. Interestingly, systemic hypertension was present, as was also observed in our previous large kindred. AMPK regulates endothelial nitric oxide synthase (eNOS), a key regulator of blood pressure homeostasis.13 The eNOS mouse knockout model exhibits a phenotype of hypertension and hypertrophy.14 Thus, impaired regulation of eNOS may induce hypertrophy and hypertension.
|
Acknowledgments |
|---|
This study was supported in part by the Effie and Woffard Cain Foundation. We are indebted to the family who volunteered to participate in the study. We greatly appreciate the assistance of Drs Carlos Rizo-Patron, Sudhir Amaram and Veronika Bachanova and the administrative assistance of Moira Long and Debbie Graustein.
|
Footnotes |
|---|
Guest Editor for this article was Douglas P. Zipes, MD, Indiana University School of Medicine, Indianapolis.
Received September 10, 2001; revision received November 5, 2001; accepted November 5, 2001.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Wolff L, Parkinson J, White PD. Bundle branch block with short PR interval in healthy young people prone to paroxysmal tachycardia. Am Heart J. 1930; 5: 686–704.
2. Ludomirsky A, Garson A, Jr. Supraventricular Tachycardia.In: Gillette PC, Garson A, Jr, eds. Pediatric Arrhythmias: Electrophysiology and Pacing. Philadelphia, Pa: W.B. Saunders; 1999: 380–426.
3.
Wiedermann CJ, Becker AE, Hopferwieser T, et al. Sudden death in a young competitive athlete with Wolff-Parkinson-White syndrome. Eur Heart J. 1987; 8: 651–655.
4.
Basso C, Corrado D, Rossi L, et al. Ventricular preexcitation in children and young adults: atrial myocarditis as a possible trigger of sudden death. Circulation. 2001; 103: 269–275.
5.
Gollob MH, Green MS, Tang A, et al. Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. N Engl J Med. 2001; 344: 1823–1864.
6. Lang T, Yu L, Tu Q, et al. Molecular cloning, genomic organization, and mapping of PRKAG2, a heart abundant gamma-2 subunit of 5'-AMP-activated protein kinase, to human chromosome 7q36. Genomics. 2000; 70: 258–263.[Medline] [Order article via Infotrieve]
7. Cheung PC, Salt IP, Davies DG, et al. Characterization of AMP-activated protein kinase gamma-subunit isoforms and their role in AMP binding. Biochem J. 2000; 346: 659–669.
8.
Blair E, Redwood CS, Ashrafian H, et al. Mutations in the gamma(2) subunit of AMP-activated protein kinase cause hypertrophic cardiomyopathy: evidence for the central role of energy comp disease pathogenesis. Hum Mol Genet. 2001; 10: 1215–1220.
9. Leclerc I, Kahn A, Doiron B. The 5'-AMP-activated protein kinase inhibits the transcriptional stimulation by glucose in liver cells, acting through the glucose response complex. FEBS Lett. 1998; 431: 180–184.[Medline] [Order article via Infotrieve]
10.
Schott JJ, Benson DW, Basson CT, et al. Congenital heart disease caused by mutations in the transcription factor NKX2-5. Science. 1998; 281: 108–111.
11. Bauernfeind RA, Wyndham CR, Swiryn SP, et al. Paroxysmal atrial fibrillation in the Wolff-Parkinson-White syndrome. Am J Cardiol. 1981; 47: 562–569.[Medline] [Order article via Infotrieve]
12. Hallows KR, Raghuram V, Kemp BE, et al. Inhibition of cystic fibrosis transmembrane conductance regulator by novel interaction with the metabolic sensor AMP-activated protein kinase. J Clin Invest. 2000; 105: 1711–1721.[Medline] [Order article via Infotrieve]
13. Chen ZP, Mitchelhill KI, Michell BJ, et al. AMP-activated protein kinase phosphorylation of endothelial NO synthase. FEBS Lett. 1999; 443: 285–289.[Medline] [Order article via Infotrieve]
14.
Shesely EG, Maeda N, Kim HS, et al. Elevated blood pressures in mice lacking endothelial nitric oxide synthase. Proc Natl Acad Sci U S A. 1996; 93: 13176–13181.
This article has been cited by other articles:
 |
|
 |
|
  K. D. Folmes, A. Y.M. Chan, D. P.Y. Koonen, T. C. Pulinilkunnil, I. Baczko, B. E. Hunter, S. Thorn, M. F. Allard, R. Roberts, M. H. Gollob, et al. Distinct Early Signaling Events Resulting From the Expression of the PRKAG2 R302Q Mutant of AMPK Contribute to Increased Myocardial Glycogen Circ Cardiovasc Genet, October 1, 2009; 2(5): 457 - 466. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Hatcher and C. T. Basson Specification of the Cardiac Conduction System by Transcription Factors Circ. Res., September 25, 2009; 105(7): 620 - 630. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Kirchhof, J. Bax, C. Blomstrom-Lundquist, H. Calkins, A. J. Camm, R. Cappato, F. Cosio, H. Crijns, H.-C. Diener, A. Goette, et al. Early and comprehensive management of atrial fibrillation: Proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled 'research perspectives in atrial fibrillation' Europace, July 1, 2009; 11(7): 860 - 885. [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Barth and G. F. Tomaselli Cardiac Metabolism and Arrhythmias Circ Arrhythm Electrophysiol, June 1, 2009; 2(3): 327 - 335. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Nakano, H. Nakano, and K.R. Chien Multipotent Islet-1 Cardiovascular Progenitors in Development and Disease Cold Spring Harb Symp Quant Biol, February 9, 2009; (2009) sqb.2008.73.055v1. [Abstract] [PDF]
|
|
|
|
 |
|
 A. J. Camm, P. Kirchhof, G. Y.H. Lip, I. Savelieva, and S. Ernst CHAPTER 29 Atrial Fibrillation ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H Watkins, H Ashrafian, and W J McKenna The genetics of hypertrophic cardiomyopathy: Teare redux Heart, October 1, 2008; 94(10): 1264 - 1268. [Full Text] [PDF]
|
|
|
|
 |
|
 Y. C. Long and J. R. Zierath Influence of AMP-activated protein kinase and calcineurin on metabolic networks in skeletal muscle Am J Physiol Endocrinol Metab, September 1, 2008; 295(3): E545 - E552. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Momcilovic, S. H. Iram, Y. Liu, and M. Carlson Roles of the Glycogen-binding Domain and Snf4 in Glucose Inhibition of SNF1 Protein Kinase J. Biol. Chem., July 11, 2008; 283(28): 19521 - 19529. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. H. Young AMP-Activated Protein Kinase Conducts the Ischemic Stress Response Orchestra Circulation, February 12, 2008; 117(6): 832 - 840. [Full Text] [PDF]
|
|
|
|
|
|
M. H. Gollob Modulating Phenotypic Expression of the PRKAG2 Cardiac Syndrome Circulation, January 15, 2008; 117(2): 134 - 135. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Zheng, A. Perianayagam, D. H. Lee, M. D. Brannan, L. E. Yang, D. Tellalian, P. Chen, K. Lemieux, A. Marette, J. H. Youn, et al. AMPK activation with AICAR provokes an acute fall in plasma [K+] Am J Physiol Cell Physiol, January 1, 2008; 294(1): C126 - C135. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Viana, M. C. Towler, D. A. Pan, D. Carling, B. Viollet, D. G. Hardie, and P. Sanz A Conserved Sequence Immediately N-terminal to the Bateman Domains in AMP-activated Protein Kinase {gamma} Subunits Is Required for the Interaction with the beta Subunits J. Biol. Chem., June 1, 2007; 282(22): 16117 - 16125. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Mulligan, A. A. Gonzalez, A. M. Stewart, H. V. Carey, and K. W. Saupe Upregulation of AMPK during cold exposure occurs via distinct mechanisms in brown and white adipose tissue of the mouse J. Physiol., April 15, 2007; 580(2): 677 - 684. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Arad, C. E. Seidman, and J.G. Seidman AMP-Activated Protein Kinase in the Heart: Role During Health and Disease Circ. Res., March 2, 2007; 100(4): 474 - 488. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Bayrak, E. Komurcu-Bayrak, B. Mutlu, G. Kahveci, Y. Basaran, and N. Erginel-Unaltuna Ventricular pre-excitation and cardiac hypertrophy mimicking hypertrophic cardiomyopathy in a Turkish family with a novel PRKAG2 mutation Eur J Heart Fail, November 1, 2006; 8(7): 712 - 715. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Li, D. L. Coven, E. J. Miller, X. Hu, M. E. Young, D. Carling, A. J. Sinusas, and L. H. Young Activation of AMPK {alpha}- and {gamma}-isoform complexes in the intact ischemic rat heart Am J Physiol Heart Circ Physiol, October 1, 2006; 291(4): H1927 - H1934. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Yu, M. F. Hirshman, N. Fujii, J. M. Pomerleau, L. E. Peter, and L. J. Goodyear Muscle-specific overexpression of wild type and R225Q mutant AMP-activated protein kinase {gamma}3-subunit differentially regulates glycogen accumulation Am J Physiol Endocrinol Metab, September 1, 2006; 291(3): E557 - E565. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. B. Dyck and G. D. Lopaschuk AMPK alterations in cardiac physiology and pathology: enemy or ally? J. Physiol., July 1, 2006; 574(1): 95 - 112. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. K. Davies, D. J. Wells, K. Liu, H. R. Whitrow, T. D. Daniel, R. Grignani, C. A. Lygate, J. E. Schneider, G. Noel, H. Watkins, et al. Characterization of the role of {gamma}2 R531G mutation in AMP-activated protein kinase in cardiac hypertrophy and Wolff-Parkinson-White syndrome Am J Physiol Heart Circ Physiol, May 1, 2006; 290(5): H1942 - H1951. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ignoul and J. Eggermont CBS domains: structure, function, and pathology in human proteins Am J Physiol Cell Physiol, December 1, 2005; 289(6): C1369 - C1378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Ahmad, M. Arad, N. Musi, H. He, C. Wolf, D. Branco, A. R. Perez-Atayde, D. Stapleton, D. Bali, Y. Xing, et al. Increased {alpha}2 Subunit-Associated AMPK Activity and PRKAG2 Cardiomyopathy Circulation, November 15, 2005; 112(20): 3140 - 3148. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. C. Stanley, F. A. Recchia, and G. D. Lopaschuk Myocardial Substrate Metabolism in the Normal and Failing Heart Physiol Rev, July 1, 2005; 85(3): 1093 - 1129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. T. Murphy, J. Mogensen, K. McGarry, A. Bahl, A. Evans, E. Osman, P. Syrris, G. Gorman, M. Farrell, J. L. Holton, et al. Adenosine monophosphate-activated protein kinase disease mimicks hypertrophic cardiomyopathy and Wolff-Parkinson-White syndrome: Natural history J. Am. Coll. Cardiol., March 15, 2005; 45(6): 922 - 930. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Sidhu, Y. S. Rajawat, T. G. Rami, M. H. Gollob, Z. Wang, R. Yuan, A.J. Marian, F. J. DeMayo, D. Weilbacher, G. E. Taffet, et al. Transgenic Mouse Model of Ventricular Preexcitation and Atrioventricular Reentrant Tachycardia Induced by an AMP-Activated Protein Kinase Loss-of-Function Mutation Responsible for Wolff-Parkinson-White Syndrome Circulation, January 4, 2005; 111(1): 21 - 29. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P.P. Smits, M. W. Veldkamp, and A. A.M. Wilde Mechanisms of inherited cardiac conduction disease Europace, January 1, 2005; 7(2): 122 - 137. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Nanthakumar, Y. R. Lau, V. J. Plumb, A. E. Epstein, and G. N. Kay Electrophysiological Findings in Adolescents With Atrial Fibrillation Who Have Structurally Normal Hearts Circulation, July 13, 2004; 110(2): 117 - 123. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Yin, J. Mu, and M. J. Birnbaum Role of AMP-activated Protein Kinase in Cyclic AMP-dependent Lipolysis In 3T3-L1 Adipocytes J. Biol. Chem., October 31, 2003; 278(44): 43074 - 43080. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. V. Patel, M. Arad, I. P. G. Moskowitz, C. T. Maguire, D. Branco, J. G. Seidman, C. E. Seidman, and C. I. Berul Electrophysiologic characterization and postnatal development of ventricular pre-excitation in a mouse model of cardiachypertrophy and Wolff-Parkinson-White syndrome J. Am. Coll. Cardiol., September 3, 2003; 42(5): 942 - 951. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Arad, I. P. Moskowitz, V. V. Patel, F. Ahmad, A. R. Perez-Atayde, D. B. Sawyer, M. Walter, G. H. Li, P. G. Burgon, C. T. Maguire, et al. Transgenic Mice Overexpressing Mutant PRKAG2 Define the Cause of Wolff-Parkinson-White Syndrome in Glycogen Storage Cardiomyopathy Circulation, June 10, 2003; 107(22): 2850 - 2856. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. R. Hallows, G. P. Kobinger, J. M. Wilson, L. A. Witters, and J. K. Foskett Physiological modulation of CFTR activity by AMP-activated protein kinase in polarized T84 cells Am J Physiol Cell Physiol, May 1, 2003; 284(5): C1297 - C1308. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. E. Light, C. H.R. Wallace, and J. R.B. Dyck Constitutively Active Adenosine Monophosphate-Activated Protein Kinase Regulates Voltage-Gated Sodium Channels in Ventricular Myocytes Circulation, April 22, 2003; 107(15): 1962 - 1965. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Watkins Genetic Clues to Disease Pathways in Hypertrophic and Dilated Cardiomyopathies Circulation, March 18, 2003; 107(10): 1344 - 1346. [Full Text] [PDF]
|
|
|
|
|
|
K. R. Hallows, J. E. McCane, B. E. Kemp, L. A. Witters, and J. K. Foskett Regulation of Channel Gating by AMP-activated Protein Kinase Modulates Cystic Fibrosis Transmembrane Conductance Regulator Activity in Lung Submucosal Cells J. Biol. Chem., January 3, 2003; 278(2): 998 - 1004. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Daniel and D. Carling Functional Analysis of Mutations in the gamma 2 Subunit of AMP-activated Protein Kinase Associated with Cardiac Hypertrophy and Wolff-Parkinson-White Syndrome J. Biol. Chem., December 20, 2002; 277(52): 51017 - 51024. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Doevendans and H. J. Wellens Wolff-Parkinson-White Syndrome: A Genetic Disease? Circulation, December 18, 2001; 104(25): 3014 - 3016. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||